Zenas BioPharma, Inc. (NASDAQ: ZBIO) priced a concurrent public offering that includes $200 million of 2.50% convertible senior notes due 2032 and 5 million shares of common stock at $20 per share, with net proceeds expected to total approximately $287.5 million after underwriting discounts and commissions.
The convertible notes mature on April 1 2032, accrue semi‑annual interest at 2.50%, and can be converted into shares at an initial conversion rate of 37.7358 shares per $1,000 principal, which translates to an initial conversion price of about $26.50 per share—roughly a 32.5% premium over the equity offering price. The equity portion of the offering provides immediate capital, while the notes offer investors a lower‑rate debt instrument with upside potential if the company’s share price rises.
Proceeds will be directed toward the planned U.S. commercial launch of obexelimab for IgG4‑related disease, the advancement of orelabrutinib’s global Phase 3 programs (PriMroSe and Monarch) for progressive multiple sclerosis, and additional pipeline development and working‑capital needs. Obexelimab’s Phase 3 INDIGO trial met primary and key secondary endpoints, and the company expects to submit a Biologics License Application in Q2 2026. Orelabrutinib is in global Phase 3 trials and is also being developed for other autoimmune indications.
Zenas remains a clinical‑stage company that has not yet achieved profitability, and its latest 10‑K includes a going‑concern flag. The capital raise is therefore a critical step to extend the company’s liquidity runway, address the financial pressures highlighted in the filing, and support the late‑stage development and potential commercialization of its lead assets.
The autoimmune‑disease market is large, growing, and increasingly competitive. By securing this financing, Zenas positions itself to compete more effectively, de‑risk its pipeline, and maintain momentum toward regulatory submissions and market entry. The transaction also signals investor confidence in the company’s platform and pipeline, despite the ongoing financial challenges.
The offering is expected to close on March 31 2026, after which Zenas will begin deploying the proceeds in accordance with its stated priorities. The financing provides a substantial cash infusion that will support the company’s strategic objectives and extend its operational runway into the next several years.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.